Funding
Soft Loans and Grants
AbilityPharma shareholders include the venture capital firm Inveready, private investors and the founders of the company.
This company is capitalized by Innvierte, an investment program of CDTI, E.P.E.
This company is capitalized by Innvierte, an investment program of CDTI, E.P.E.
The company has obtained grants and soft loans from high level public institutions:
- NEBT grant from ACCIÓ, Government of Catalonia.
- Technological Innovation Nuclei grant from ACCIÓ, Government of Catalonia.
- PID soft loan from CDTI, Government of Spain.
- Innoglobal from CDTI, Government of Spain.
- Innocash from Fundación Genoma España, Government of Spain.
- ENISA (National Innovation Company), Ministry of Industry, Energy and Tourism, Government of Spain.
- Investment Readiness program from ACC1Ó, Government of Catalonia.
- Torres-Quevedo grants from MINECO, Government of Spain.
- International Talent grant from Biocat (Bioregion Catalonia), Government of Catalonia.
- Inncorpora soft loan from the Ministry of Economy and Competitivity, Government of Spain.
- Innpacto soft loan from the Ministry of Economy and Competitivity, Government of Spain.
- Retos soft loan from the Ministry of Economy and Competitivity, Government of Spain.
 |
 |
 |
|
|
 |
 |
 |
|
 |
Ability Pharmaceuticals participates in the project "New therapeutic approaches based on derivatives of essential fatty acids targeted to unmet needs in oncological and neurological diseases" funded by the INNPACTO call of the Spanish Research Program (MINECO) with dossier number IPT- 2012-0614-010000.
Ability Pharmaceuticals has received grants for recruitment : Torres Quevedo (PTQ-11-04900, PTQ-12-05453), Inncorpora (INC-TU-2012-2617) and Emplea (EMP-2015-4578 -2015 and EMP-2015-4569).
The Ministry of Science, Innovation and Universities, within the State Plan for Scientific and Technical Research and Innovation 2013-2016, granted assistance to the project "NEW STRATEGIES TO INCREASE EFFECTIVENESS OF TREATMENTS WITH ABTL0812" led by Ability Pharmaceuticals SL with file number RTC -2017-6261-1.
This project has been funded by the Ministry of Science, Innovation and Universities within the RETOS-COLLABORATION Subprogram, Call 2017.
The project is co-financed by the European Union with the aim of promoting technological development, innovation and quality research.
LATEST NEWS
05.11.2020
Press Release
AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + info
22.10.2020
Press Release
AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info
22.09.2020
Press Release
ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + info
09.06.2020
Press Release
AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info
25.03.2020
Press Release
AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info
12.09.2019
Press Release
AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
31.05.2019
Press Release
Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
04.02.2019
Press Release
Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + info
30.01.2019
Press Release
Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference + info
